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Abstract
Background: Procedural sedation and analgesia (PSA) is used to attenuate the pain and distress that may otherwise be
experienced during diagnostic and interventional medical or dental procedures. As the risk of adverse events increases with
the depth of sedation induced, frequent monitoring of level of consciousness is recommended. Level of consciousness is
usually monitored during PSA with clinical observation. Processed electroencephalogram-based depth of anaesthesia (DoA)
monitoring devices provide an alternative method to monitor level of consciousness that can be used in addition to clinical
observation. However, there is uncertainty as to whether their routine use in PSA would be justified. Rigorous evaluation of
the clinical benefits of DoA monitors during PSA, including comprehensive syntheses of the available evidence, is therefore
required. One potential clinical benefit of using DoA monitoring during PSA is that the technology could improve patient
safety by reducing sedation-related adverse events, such as death or permanent neurological disability. We hypothesise that
earlier identification of lapses into deeper than intended levels of sedation using DoA monitoring leads to more effective
titration of sedative and analgesic medications, and results in a reduction in the risk of adverse events caused by the
consequences of over-sedation, such as hypoxaemia. The primary objective of this review is to determine whether using
DoA monitoring during PSA in the hospital setting improves patient safety by reducing the risk of hypoxaemia (defined as
an arterial partial pressure of oxygen below 60 mmHg or percentage of haemoglobin that is saturated with oxygen [SpO2]
less than 90 %). Other potential clinical benefits of using DoA monitoring devices during sedation will be assessed as
secondary outcomes.
Methods/design: Electronic databases will be systematically searched for randomized controlled trials comparing the
use of depth of anaesthesia monitoring devices with clinical observation of level of consciousness during PSA. Language
restrictions will not be imposed. Screening, study selection and data extraction will be performed by two independent
reviewers. Disagreements will be resolved by discussion. Meta-analyses will be performed if suitable.
Discussion: This review will synthesise the evidence on an important potential clinical benefit of DoA monitoring during
PSA within hospital settings.
Systematic review registration: PROSPERO CRD42015017251
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Background
Description of the condition
The aim of procedural sedation and analgesia (PSA) is to
produce “a state of drug-induced tolerance of uncomfort-
able or painful diagnostic or interventional medical, dental
or surgical procedures” (p.1) [1]. PSA is generally described
as a continuum, with the risk of serious sedation-related
adverse events, such as death or permanent neurological
disability, increasing with the depth of sedation induced [2].
Prompt detection of lapses into deeper than intended levels
of sedation is required so that corrective interventions can
be implemented. For this reason, frequent monitoring of
level of consciousness is recommended [1, 2]. Level of con-
sciousness is usually monitored during PSA by clinical ob-
servation, which is performed by judging a sedated patient’s
response to increasing levels of stimulation [3]. A standar-
dised sedation assessment scale that assigns a numerical
rank to observable clinical behaviours that are known to be
associated with changes in the level of consciousness can
be used to supplement clinical observation methods for
assessing changes in level of consciousness during PSA.
Processed electroencephalogram-based depth of anaesthesia
(DoA) monitoring devices provide an alternative method to
monitor level of consciousness that can be used in addition
to clinical observation.
Description of the intervention
The most commonly used DoA monitoring device is the
bispectral index (BIS™ Covidien, Inc., Boulder, CO, USA)
[4]. The device calculates a numerical derivative from brain
electrical activity. It is calculated from an electroencephalo-
gram measured at the forehead. BIS values range between
0, which represents a state of ‘no detectable brain electrical
activity’, and 100, which represents the ‘awake’ state [5].
Values below 60 correspond to ‘deep’ sedation [6]. BIS
monitoring during surgery with general anaesthesia results
in several clinically important benefits such as reduced risk
of intra-operative awareness [7], reduced anaesthetic doses
and reduced recovery time [8]. Results of recent studies in
patients receiving general and regional anaesthesia have
suggested there may even be a survival benefit from pre-
venting deep levels of sedation during general anaesthesia,
as indicated by BIS monitoring [9, 10].
Other DoA monitors which use proprietary algorithms
to process EEG information include the E-Entropy (GE
Healthcare) and Narcotrend-Compact M monitors (MT
Monitor Technik). The National Institute for Health and
Care Excellence (NICE) has concluded that the evidence
for the use of the latter two monitors is less certain than
for BIS in patients receiving general anaesthesia [11].
However, the use of EEG monitors (including E-Entropy,
Narcotrend-Compact M and BIS) are recommended for
all patients receiving total intravenous anaesthesia [11].
Similar to the BIS, both of these monitors produce
values to represent different states of the depth of
anaesthesia.
Why is it important to do this review?
The utility of DoA monitoring for sedated patients has
been evaluated in a number of clinical areas within the hos-
pital setting, such as the endoscopy suite [12] and radiology
department [13]. Most of the available evidence relates
to the BIS monitor. However, there remains considerable
uncertainty as to whether the clinical benefits of DoA
monitors justify their use [3]. Rigorous evaluation of the
potential clinical benefits, including comprehensive syn-
theses of the available evidence, is required. To the au-
thors’ knowledge, there are no systematic reviews on the
utility of DoA monitors for procedural sedation in the
published literature. Arguably, the most important poten-
tial clinical benefit of using DOA monitoring during PSA
is that this technology could improve patient safety by
reducing sedation-related adverse events, such as death or
permanent neurological disability. We hypothesise that
earlier identification of lapses into deeper than intended
levels of sedation using DoA monitors leads to more ef-
fective titration of sedative and analgesic medications
resulting in a reduction in the risk of sedation-related
adverse events caused by over-sedation.
The frequency with which serious sedation-related ad-
verse events occur is too low for this endpoint to be
used as the primary outcome in randomized controlled
trials or meta-analyses of PSA. However, it has been
identified that inadequate oxygenation/ventilation is the
most common reason for injury associated with sedation
that is administered in the procedural setting [14]. It has
been posited that surrogate outcomes must be in the
causal pathway of injury with correlation alone not being
sufficient [15]. A recent study reported that arterial oxy-
gen saturation is the most important physiological par-
ameter in assessment of risk of adverse outcomes during
sedation [16]. For this reason, we determined that reduc-
tion in episodes of hypoxaemia would be the most suit-
able surrogate marker to investigate the potential patient
safety benefits that may be associated with using DoA
monitors of depth of sedation during PSA.
Objectives
The primary objective of this review is to determine
whether using DoA monitoring during PSA in the hos-
pital setting improves patient safety by reducing the risk
of hypoxaemia (defined as an arterial partial pressure of
oxygen below 60 mmHg or percentage of haemoglobin
that is saturated with oxygen [SpO2] less than 90 %).
The secondary objective of this review is to synthesise
the available evidence on other potential clinical benefits
of DoA monitoring during sedation. Adverse effects of
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DoA monitoring will not be specifically examined in this
review.
Methods/design
A systematic review and meta-analyses adhering to the
protocol outlined below will be conducted. Any differences
between this protocol and the review will be reported.
Criteria for considering studies for this review
Types of studies
Parallel and crossover randomized controlled trials
comparing DoA monitoring with clinical assessment for
the management of patients receiving procedural sed-
ation and analgesia will be included. Studies that tested
non-inferiority or equivalence hypotheses will be ex-
cluded because DoA monitoring is used in addition to
standard monitoring not as a direct alternative. Cluster-
randomised, non-randomised or quasi-randomised trials
will be excluded.
Types of clinical settings
Studies conducted in any inpatient or outpatient setting
where PSA is used in a hospital will be included. Exam-
ples of clinical settings include emergency departments,
medical imaging departments, endoscopy suites and car-
diac catheterisation laboratories. Dental surgeries/clinics
will be excluded due to the potentially confounding in-
fluence that the different staffing profiles between these
types of settings may have on clinical outcomes (i.e., the
presence of a medical doctor versus a dentist).
Types of participants
Studies that included patients (adults or children) who
received procedural sedation and analgesia (with or
without local anaesthesia) will be included in the review.
Studies that included patients who received general or
regional anaesthesia will be excluded from the review.
Types of intervention
Patients whose sedation was managed by a strategy where
DoA monitoring, such as bispectral index, E-Entropy and
Narcotrend, was used (in addition to clinical judgement
and/or a specified clinical sedation assessment tool).
Types of comparison
Patients whose sedation was managed without use of
DoA monitoring (only clinical judgement and/or a spe-
cified clinical sedation assessment tool was used).
Types of outcome measures
Primary outcome:
 Hypoxaemia (arterial partial pressure of oxygen
below 60 mmHg or percentage of haemoglobin that
is saturated with oxygen [SpO2] less than 90 % for
any period of time).
Secondary outcomes:
 Hypotension (systolic blood pressure less than
90 mmHg).
 Amount of sedative and analgesic medications used
(a separate analysis will be undertaken for each
medication).
 Duration of recovery (Defined as the time from end
of procedure until Aldrete discharge recovery score
more than 7. As outcomes will not form part of
eligibility assessment, it will be possible to include
other definitions for duration of recovery if our a-
priori definition has not been reported consistently.
In this circumstance, any changes between the
protocol and the review will be outlined clearly in
the report).
 Unable to complete procedure as it was planned due
to inadequate sedation.
 Sedation-related adverse events (death, neurological
deficits).
A possible mechanism of injury that could also be attenu-
ated with improved titration of medications for PSA is
organ hypoperfusion [17]. As such, we will use a standard
definition for hypotension as a secondary outcome. As we
hypothesise that changing clinicians’ decision-making re-
garding medication titration is the moderating mechanism
for clinical benefits associated with DOA monitoring dur-
ing PSA, a secondary outcome will be the amount of seda-
tive and analgesic medication used. We also hypothesise
that intervening at the onset of an episode of respiratory
depression that would have resolved spontaneously is coun-
terproductive and could result in inadequate sedation. For
this reason, we will investigate the number of procedures
needing to be abandoned due to inadequate sedation as a
secondary outcome.
Search methods for identification of studies
We will identify published, unpublished and ongoing
studies by searching the following databases:
 The Cochrane Central Register of Controlled Trials
(CENTRAL) (1999 (established) to present);
 MEDLINE (OvidSP) (1966 to present);
 CINAHL (EBSCOhost) (1982 to present);
 ClinicalTrials.gov; and
 World Health Organization International Clinical
Trials Registry Platform.
The search strategy (Appendices 1, 2 and 3) has been de-
signed by applying the guidance of the Cochrane Handbook
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for Systematic Reviews of Interventions, Chapter 6.4 [18].
Language restrictions will not be imposed for the search. If
the study has been considered as potentially eligible based
on the abstract, we will attempt to either have the article
translated or have the required data extracted. If this cannot
be done, we will include this in the report of the review.
Data collection and analysis
Selection of studies
Initial screening of titles and abstracts will be performed
by two independent reviewers (AC and JS). Full copies of
all studies that meet the inclusion criteria will be obtained
for further assessment. Second screening of full text arti-
cles will be performed by two independent reviewers (AC
and JS) applying all inclusion and exclusion criteria out-
lined in the review protocol (Additional file 1). Disagree-
ment on eligibility will be resolved by discussion.
Data extraction and management
AC and JS will independently extract data using the data
extraction form (Additional file 1). Any differences of
opinion will be reconciled by mutual agreement. Data will
be entered into a database (Review Manager (RevMan),
Version 5) for statistical analysis.
Assessment of risk of bias in included studies
AC and JS will undertake the risk of bias assessment of
the included studies independently, as guided by the
Cochrane Handbook for Systematic Reviews of Interven-
tions [18]. The Cochrane risk of bias tool will be used to
assign a judgment about the degree of risk (low risk of
bias, high risk of bias and unclear risk of bias) (Additional
file 1) [18].
Measures of treatment effect
When the measure of the outcome is sufficiently consist-
ent across trials, we will use risk ratios for dichotomous
data and mean difference or standardised mean difference
for continuous data with corresponding 95 % confidence
intervals (CIs).
Unit/scale of analysis issues
The unit of analysis is based on the individual patient
(the unit that was randomised for comparison of inter-
ventions). We will use pre-crossover data for included
trials that used a crossover design.
Dealing with missing data
It is unlikely that there will be missing data for the out-
comes selected for this review, as they are measured
during the procedure. A possible reason for missing
data could be malfunction of monitoring equipment
resulting in a loss of data about intra-procedural physio-
logical parameters. Therefore, we will attempt to perform
intention-to-treat (ITT) analyses wherever possible, and if
studies do not report withdrawals, we will assume there
were none.
Assessment of heterogeneity
To assess statistical heterogeneity we will apply the chi-
squared test, as a low p value is evidence of the hetero-
geneity of intervention effects. In addition to statistical
assessments, we will qualitatively review studies by
examining variability in study participants, interven-
tions and outcomes. In the absence of clinical hetero-
geneity, we will use the I2 statistic to describe the
percentage of total variation across studies that is due to
the heterogeneity rather than chance. An I2 value
greater than 50 % will be considered significant hetero-
geneity. We will also use visual inspection of the graph-
ical representation of study results with their 95 % CIs
to assess heterogeneity.
Assessment of reporting biases
We will avoid publication bias by comprehensive litera-
ture searching and use of study registries [19]. We will
attempt to obtain and include data from unpublished
work, and no language restriction will be imposed to re-
duce the risk of reporting bias. We will use a graphical dis-
play (funnel plot if greater than ten studies are included)
of the size of treatment effect against the precision of the
trial to investigate publication bias by looking for signs of
asymmetry. If there is asymmetry, we will look for reasons
other than publication bias.
Data synthesis
First we will consider the appropriateness of undertak-
ing meta-analysis in the presence of significant clinical
or statistical heterogeneity. We will use the fixed-effect
model meta-analysis except where statistical heterogen-
eity is identified, in which case we will use the random-
effects model [18]. We will perform the meta-analyses
using RevMan software (Version 5).
Subgroup analysis
We will consider conducting subgroup analysis if the
data indicates clinical or statistical (I2 > 50 %) heterogen-
eity based on:
 age (adults or children);
 use of supplemental oxygen (used routinely or not);
 use of end-tidal carbon dioxide monitoring
(used or not);
 the type of sedation regimen used (propofol,
benzodiazepine, benzodiazepine and opioid
combination, ketamine, dexmedetomidine, other)
 the type of DoA monitoring device used; and
 the type of procedure (diagnostic or interventional).
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Summary of findings
We will present study findings in a standard ‘Summary
of findings’ (SOF) table, which will include a list of the
primary outcomes, a measure of the typical burden of
these outcomes, the absolute and relative magnitude of
effect, the numbers of participants and studies address-
ing each outcome and a grade for the overall quality of
the body of evidence for each outcome. Space will be
provided for comments. We will use the principles of
the Grades of Recommendation, Assessment, Develop-
ment and Evaluation (GRADE) system [20] to assess the
quality of the body of evidence associated with specific
outcomes (hypoxaemia, hypotension, sedation doses,
duration of recovery and procedural completion) and
will construct the SoF table using GRADE software. The
GRADE approach appraises the quality of a body of evi-
dence according to the extent to which one can be
confident that an estimate of effect or association re-
flects the item being assessed. The quality of the body of
evidence considers within-study risk of bias (methodo-
logical quality), directness of the evidence, heterogeneity
of the data, precision of effect estimates and risk of pub-
lication bias.
Discussion
To the best of our knowledge, this systematic review will
examine, for the first time, the current state of evidence
on the benefits to patient safety that may be associated
with using DoA monitors instead of clinical observation
to monitor level of consciousness during PSA. Reducing
the risk of the most common antecedent event (hypoxia
from inadequate oxygenation or ventilation) for sedation-
related death and permanent neurological deficits would
be a strong indicator that DoA monitors are likely to im-
prove patient safety during PSA. For this reason, results
from this systematic review will be valuable for clinical
practice and research. A synthesis of the existing evidence
will help clinicians who use PSA to integrate relevant find-
ings into their daily practice. Gaps in the literature will
also be identified, which could be addressed in future
research.
Appendix 1: Search strategy for CENTRAL
#1 MeSH descriptor: [Electroencephalography] explode
all trees
#2 (EEG or BIS or electroence*):ti,ab or (brain near
monitor*) or bispectral index or e-entropy or Narco-
trend or depth of anesthesia:ti,ab
#3 #1 or #2
#4 MeSH descriptor: [Conscious Sedation] explode all
trees
#5 MeSH descriptor: [Deep Sedation] explode all trees
#6 #4 or #5
#7 #3 and #6
Appendix 2: MEDLINE (EBSCOhost) search
strategy
1. exp Electroencephalography/ or (EEG or BIS or
electroence*).ti,ab. or (brain adj3 monitor*).mp. or
“bispectral index” or e-entropy or Narcotrend or
depth of anesthesis.mp.
2. Conscious Sedation/ or sedat*.ti,ab.
3. 1 and 2
Appendix 3: CINAHL (EBSCOhost) search strategy
S1 (MH “Electroencephalography”) OR (EEG or BIS or
electroence*) or (brain N3 monitor*) or “bispectral index”
or e-entropy or Narcotrend or “depth of an?sthes*”)
S2 AB (sedat*) OR (MH “Conscious Sedation”)
S3 (random* or ((clinical or controlled) N3 trial*) or
placebo* or prospective* or multicenter) or (blind* or
mask*) N3 (single or double)
S4 S1 and S2 and S3
Additional file
Additional file 1: Study eligibility, data extraction form and quality
assessment.
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